Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD

In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo. To demonstrate the robustness of this finding, using pre-specified sensitivity and subgroup analyses. N-MOmentum is a prospecti...

Full description

Bibliographic Details

Published in:	Multiple sclerosis Vol. 27; no. 13; p. 2052
Main Authors:	Cree, Bruce Ac, Bennett, Jeffrey L, Kim, Ho Jin, Weinshenker, Brian G, Pittock, Sean J, Wingerchuk, Dean, Fujihara, Kazuo, Paul, Friedemann, Cutter, Gary R, Marignier, Romain, Green, Ari J, Aktas, Orhan, Hartung, Hans-Peter, Williams, Ian M, Drappa, Jorn, She, Dewei, Cimbora, Daniel, Rees, William, Ratchford, John N, Katz, Eliezer
Format:	Journal Article
Language:	English
Published:	England 01.11.2021
Subjects:	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Aquaporin 4 Humans Neuromyelitis Optica - drug therapy Prospective Studies clinical trial patient demographics Attack risk neuromyelitis optica spectrum disorder neuromyelitis optica sensitivity analyses Devic’s disease inebilizumab
ISSN:	1477-0970, 1477-0970
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!